Part B “Evidence Development” Plan Needs Defined Scope – Manufacturers
Executive Summary
The Centers for Medicare & Medicaid Services needs to more clearly define the circumstances for applying a determination of coverage with evidence development for Medicare Part B-covered drugs, BIO and PhRMA say in comments on a draft guidance
You may also be interested in...
CMS Splits Coverage With Evidence Development Into Two Categories
Medicare is offering added flexibility to pay for research-related expenses that arise in the clinical trials conducted for a Part B national coverage decision, under revisions to Medicare's coverage with evidence development policy, released July 12
CMS Splits Coverage With Evidence Development Into Two Categories
Medicare is offering added flexibility to pay for research-related expenses that arise in the clinical trials conducted for a Part B national coverage decision, under revisions to Medicare's coverage with evidence development policy, released July 12
PhRMA’s Evidence-Based Medicine Principles Emphasize Individual Decisions
The Pharmaceutical Research & Manufacturers of America's principles for the use of evidence-based medicine emphasize that such data be used to "empower" patients and physicians